Nitec's Lodotra positive in second Phase III trial
This article was originally published in Scrip
Executive Summary
Nitec Pharma's circadian timed-release rheumatoid arthritis product, Lodotra (prednisone), has met its primary endpoint in the second of two Phase III trials designed for a US filing.